Brief: Kleo Pharmaceuticals Secures $21 Mln To Advance Novel Small Molecule Cancer Immunotherapies
13/11/2018 16:25
Nov 13 (Reuters) - Kleo Pharmaceuticals:
* KLEO PHARMACEUTICALS SECURES $21 MILLION TO ADVANCE NOVEL
SMALL
MOLECULE CANCER IMMUNOTHERAPIES
Source text for Eikon: ID:nPn2lTqtza
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner